Mamazole 2.5 mg

Mamazole 2.5 mg Tablet is an anti-cancer medicine containing letrozole 2.5 mg. It is used as a hormonal treatment for a particular type of breast cancer that is sensitive to estrogen especially in postmenopausal women.
Mamazole is formulated to reduce estrogen production. This may help control the growth of hormone receptor-positive breast cancer cells as these cells can rely on estrogen for stimulation and growth.

Key Features

How does Mamazole 2.5 mg work?

Mamazole reduces estrogen by blocking aromatase an enzyme involved in estrogen formation after menopause. Lower estrogen levels can reduce hormonal stimulation of breast cancer cells that have estrogen receptors.
It does not act by directly killing cancer cells. Instead it changes the hormonal environment that may support the growth of estrogen-sensitive cancer cells.

Usage

Take Mamazole 2.5 mg exactly as recommended. Swallow the tablet with water, with or without food, and try to take it at the same time every day. Do not crush or alter the tablet unless a healthcare professional specifically instructs you to do so.

Dosage 

For many approved breast cancer indications the usual dose is Mamzole 2.5 mg once daily. The oncologist will decide the treatment duration and whether the medicine should be continued based on regular clinical assessment.

Side effects

Common or clinically relevant side effects can include:

• Dizziness  
• Nausea  
• Hair thinning  
• Swelling of the extremities  
• Bone thinning or fracture risk with prolonged treatment
• Raised cholesterol  
• Hot flushes  
• Joint stiffness or joint pain  
• Fatigue  
• Headache

Contact the treating team if symptoms are severe, persistent or accompanied by a rash, facial swelling, breathing difficulty, chest discomfort or jaundice.

Interactions

Avoid starting or stopping any medicine without discussing it with the oncologist. Estrogen-containing products may interfere with the estrogen-lowering purpose of Mamazole.
Key Drug Interactions

• Tamoxifen: Co-administering tamoxifen (another breast cancer medication) significantly lowers the concentration of letrozole in your blood, making Mamazol less effective. 
• Estrogen-Containing Therapies – Hormone replacement therapy (HRT), oral contraceptives and estrogen creams directly counteract Mamazol. They raise estrogen levels reversing the therapeutic effects of the drug. 
• Other aromatase inhibitors – Mamazole is not recommended to be taken together with drugs such as anastrozole or exemestane due to the serious increase in side effects without any added benefits.
• Certain Antidepressants – Medications like citalopram or escitalopram should be discussed with your doctor as some antidepressants can interfere with overall treatment tolerability or efficacy.

 Food and Alcohol Interactions

• Food: Letrozole has no known direct food interactions. You can take Mamazol with or without food. However taking it with a meal can sometimes help reduce mild nausea. 
• Alcohol: Alcohol does not have a direct chemical interaction, but it can worsen the dizziness, hot flashes and drowsiness caused by Mamazol.

Pharmacokinetics

Mamazol 2.5 mg contains letrozole, an oral aromatase inhibitor characterized by:

• Absorption: Rapidly and completely absorbed from the gut; food does not change absorption.
• Distribution: Weakly bound to blood proteins; has a large volume of distribution (about 1.9 L/kg). 
• Metabolism: Cleared mostly by the liver via the CYP450 system into an inactive carbinol metabolite.
• Excretion: About 90% of the dose passes into the urine as the inactive glucuronide metabolite.
• Half-life: Time to terminal elimination, about 2 days.

Precautions

• Do not use during pregnancy  
• Discuss contraception requirements if pregnancy is possible  
• Avoid breastfeeding during therapy and for at least three weeks after stopping  
• Inform the doctor if there is osteoporosis, a previous fracture, liver impairment, or high cholesterol  
• Periodic bone-density assessment may be considered during extended treatment  
• Be careful with driving if dizziness, sleepiness, or fatigue occurs 

Conclusion

Mamazole 2.5 mg is a letrozole-based hormonal therapy that may help manage estrogen-sensitive breast cancer in appropriate postmenopausal patients. Consistent daily use, specialist guidance, and monitoring for joint symptoms, bone density changes, cholesterol levels and other treatment-related concerns remain important throughout therapy.

FAQs